X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Lead Product(s): Ferric Carboxymaltose
Therapeutic Area: Hematology Product Name: Orofer
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 16, 2022
Details:
The company launched generic version of sucroferric oxyhydroxide tablets, indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Lead Product(s): Iron Sucrose
Therapeutic Area: Nephrology Product Name: Dynulta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
